BCR-ABL by PCR (Quantitative) at Test Zone Diagnostic Center

BCR-ABL by PCR (Quantitative) at Test Zone Diagnostic Center

The BCR-ABL by PCR (Quantitative) test is a highly sophisticated molecular diagnostic assay designed to detect and quantify the BCR-ABL1 fusion transcript in patients suspected of or being treated for specific hematological malignancies. This test is of paramount importance in the clinical management of Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL). By utilizing advanced Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) technology, Test Zone Diagnostic Center in Lahore, Pakistan, provides clinicians and patients with highly precise, reliable, and clinically actionable data to guide targeted therapeutic interventions.

At the molecular level, the BCR-ABL1 fusion gene is the result of a reciprocal translocation between chromosomes 9 and 22, designated as t(9;22)(q34.1;q11.2). This genetic rearrangement brings together the Abelson murine leukemia viral oncogene homolog 1 (ABL1) gene from chromosome 9 and the breakpoint cluster region (BCR) gene from chromosome 22. The resulting chimeric chromosome is historically known as the Philadelphia chromosome. The fusion gene transcribes a novel chimeric messenger RNA (mRNA) that is subsequently translated into a fusion protein with constitutive tyrosine kinase activity. This abnormal protein continuously phosphorylates downstream targets, activating signaling pathways such as RAS/MAPK, JAK/STAT, and PI3K/AKT. These pathways drive uncontrolled cellular proliferation, inhibit programmed cell death (apoptosis), and alter cell-to-extracellular matrix adhesion, leading to the characteristic expansion of leukemic clones in the bone marrow and peripheral blood.

The quantitative measurement of BCR-ABL1 transcripts is the gold standard for monitoring the efficacy of Tyrosine Kinase Inhibitor (TKI) therapies, such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib. The test measures the ratio of BCR-ABL1 fusion transcripts to an endogenous reference gene (typically ABL1, GUSB, or BCR) in the patient’s sample. This ratio is then converted to the International Scale (IS), expressed as a percentage (BCR-ABL1/ABL1 % IS), utilizing a laboratory-specific conversion factor calibrated against international standards. This standardization allows for direct comparison of results across different laboratories globally, ensuring consistent clinical decision-making. The clinical value of this assay lies in its extraordinary sensitivity, capable of detecting one leukemic cell among 100,000 or more normal cells, making it indispensable for identifying minimal residual disease (MRD) and predicting clinical relapse long before cytogenetic or hematologic recurrence becomes apparent.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest accuracy and integrity of the molecular analysis, patients undergoing the BCR-ABL by PCR (Quantitative) test at Test Zone Diagnostic Center should observe the following preparation guidelines:

• No Fasting Required: There is no requirement for dietary fasting prior to this blood test. Patients may consume food and liquids normally.
• Hydration: Adequate hydration is highly recommended. Drinking plenty of water before the procedure makes venipuncture easier by expanding blood volume and improving vein visibility.
• Medication History: Patients must inform the healthcare team of all current medications, particularly Tyrosine Kinase Inhibitors (TKIs), chemotherapy agents, or immunosuppressants. Do not alter or discontinue any prescribed medication regimen unless explicitly instructed by the treating oncologist or hematologist.
• Prior Test Results: If available, patients should bring previous BCR-ABL quantitative reports, complete blood count (CBC) results, and bone marrow biopsy reports to facilitate clinical correlation by the molecular pathology team.
• Avoid Stress: While the test itself is a standard blood draw, minimizing physical and emotional stress prior to the collection is beneficial for overall patient comfort.

During the Procedure

The collection of the biological specimen for BCR-ABL quantitative analysis is a straightforward, safe, and standardized process performed by experienced phlebotomists at Test Zone Diagnostic Center:

• Patient Positioning: The patient is comfortably seated in a specialized phlebotomy chair, and the arm is positioned on a supportive armrest to ensure stability.
• Site Selection and Sanitization: The phlebotomist identifies a suitable vein, typically in the antecubital fossa (the crease of the elbow). The skin over the selected vein is thoroughly cleansed with an antiseptic solution (such as 70% isopropyl alcohol) to prevent microbial contamination.
• Sample Collection: A sterile, single-use needle attached to a vacuum collection tube is inserted into the vein. For BCR-ABL molecular testing, blood is collected in specialized tubes containing ethylenediaminetetraacetic acid (EDTA) as an anticoagulant (usually purple-top tubes). EDTA is critical because it preserves cellular integrity and prevents the activation of enzymes that could degrade RNA.
• Volume Requirements: Typically, 3 to 5 milliliters of peripheral blood is collected. In some clinical scenarios, a bone marrow aspirate sample may be utilized instead of peripheral blood, which is collected by a hematologist under local anesthesia.
• Post-Collection Care: Once the required volume is obtained, the needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile gauze pad to stop bleeding. A small adhesive bandage is applied.
• Safety and Comfort: The entire venipuncture process takes less than five minutes. Patients may experience a mild, brief pinching sensation during needle insertion. The risk of complications is extremely low, limited to minor bruising or localized soreness at the puncture site.
• Specimen Transport: Because RNA is highly susceptible to degradation by ribonucleases (RNases) present in the blood, the collected sample is immediately labeled with unique patient identifiers and transported to the molecular diagnostics laboratory under strictly controlled temperature conditions (cold chain maintenance) to preserve RNA transcripts.

When is a BCR-ABL by PCR (Quantitative) Performed?

Initial Diagnosis of Chronic Myeloid Leukemia

The BCR-ABL by PCR (Quantitative) test is performed at the time of initial clinical suspicion of Chronic Myeloid Leukemia (CML). When a patient presents with persistent leukocytosis, splenomegaly, or unexplained fatigue, and cytogenetic analysis or fluorescent in situ hybridization (FISH) suggests the presence of the Philadelphia chromosome, this quantitative PCR assay is ordered. It establishes the baseline level of BCR-ABL1 transcripts, identifies the specific transcript isoform (such as p210 or p190), and confirms the diagnosis at the molecular level. This baseline value is critical, as all subsequent therapeutic responses are measured against it to calculate log reductions in tumor burden.

Monitoring Response to Tyrosine Kinase Inhibitor Therapy

Following the initiation of targeted therapy with Tyrosine Kinase Inhibitors (TKIs), guidelines from the European LeukemiaNet (ELN) and the National Comprehensive Cancer Network (NCCN) mandate regular molecular monitoring. The BCR-ABL by PCR (Quantitative) test is performed at defined clinical milestones—typically at 3, 6, and 12 months, and every 3 to 6 months thereafter. These intervals assess whether the patient is achieving critical molecular milestones, such as Early Molecular Response (EMR) at 3 months (BCR-ABL1 transcript level ≤ 10% IS) or Major Molecular Response (MMR) by 12 months (BCR-ABL1 transcript level ≤ 0.1% IS), which are highly predictive of long-term progression-free survival.

Detection of Minimal Residual Disease

Even when a patient achieves a complete hematologic response (normal blood counts and no splenomegaly) and a complete cytogenetic response (no Philadelphia chromosome detected in bone marrow metaphases), millions of leukemic cells may still persist in the body. The BCR-ABL quantitative PCR test is performed to detect this Minimal Residual Disease (MRD). Due to its high analytical sensitivity, the assay can quantify extremely low levels of residual leukemia, allowing clinicians to determine the depth of molecular response (e.g., MR4.0, MR4.5, or MR5.0) and assess whether the patient is a candidate for supervised treatment discontinuation or treatment-free remission (TFR).

Evaluation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Approximately 20% to 30% of adult patients and a smaller percentage of pediatric patients with Acute Lymphoblastic Leukemia (ALL) harbor the Philadelphia chromosome (Ph+ ALL). In these patients, the BCR-ABL by PCR (Quantitative) test is performed at diagnosis to identify the fusion transcript (most commonly the p190 isoform) and subsequently used to monitor the clearance of leukemic blasts during induction chemotherapy, consolidation therapy, and TKI treatment. Quantitative monitoring in Ph+ ALL is highly prognostic and is critical in determining the timing and necessity of allogeneic hematopoietic stem cell transplantation.

Surveillance for Disease Relapse and Resistance Mutations

In patients who have achieved a stable molecular response, routine surveillance using the BCR-ABL by PCR (Quantitative) test is performed to detect early signs of molecular relapse. A significant, confirmed rise in BCR-ABL1 transcript levels (such as a 1-log increase or loss of MMR) serves as an early warning sign of therapeutic failure. This clinical indication prompts immediate investigation into patient adherence, or the development of point mutations within the BCR-ABL1 kinase domain (such as the gatekeeper T315I mutation) that confer resistance to standard TKIs, allowing for timely therapeutic adjustments before clinical or hematologic relapse occurs.

What Does a BCR-ABL by PCR (Quantitative) Detect?

The BCR-ABL by PCR (Quantitative) assay is designed to detect, characterize, and quantify several critical molecular parameters essential for the clinical management of leukemia. Specifically, the test detects and measures:

• BCR-ABL1 Fusion Transcripts: Confirms the presence of the chimeric mRNA resulting from the t(9;22) translocation.
• Transcript Quantification: Measures the exact number of BCR-ABL1 fusion gene copies in the clinical sample.
• Reference Gene Copy Number: Quantifies the copy number of an endogenous control gene (typically ABL1) to ensure sample quality and sufficient RNA input.
• BCR-ABL1/ABL1 Ratio: Calculates the mathematical ratio of fusion transcripts to control transcripts, correcting for variations in sample cellularity and RNA extraction efficiency.
• International Scale (IS) Percentage: Converts the raw ratio into a standardized percentage (% IS) using a laboratory-specific conversion factor, enabling global clinical comparison.
• p210 Fusion Isoform (b2a2/b3a2): Detects the major breakpoint transcripts characteristic of more than 95% of CML cases.
• p190 Fusion Isoform (e1a2): Detects the minor breakpoint transcripts commonly associated with Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).
• p230 Fusion Isoform (e19a2): Identifies the rare micro breakpoint transcript associated with Chronic Neutrophilic Leukemia (CNL) or atypical CML.
• Baseline Tumor Burden: Establishes the pre-treatment molecular load of the disease at initial diagnosis.
• Early Molecular Response (EMR): Detects whether transcript levels have fallen to 10% IS or less within the first 3 months of TKI therapy.
• Major Molecular Response (MMR / MR3.0): Detects a 3-log reduction in transcripts, equivalent to a BCR-ABL1 level of 0.1% IS or less.
• Deep Molecular Response 4.0 (MR4.0): Detects a 4-log reduction in transcripts, equivalent to a BCR-ABL1 level of 0.01% IS or less.
• Deep Molecular Response 4.5 (MR4.5): Detects a 4.5-log reduction in transcripts, equivalent to a BCR-ABL1 level of 0.0032% IS or less.
• Complete Molecular Response (CMR): Identifies the absence of detectable BCR-ABL1 transcripts within the limits of the assay’s sensitivity.
• Minimal Residual Disease (MRD): Detects subclinical levels of leukemia cells during clinical remission.
• Molecular Relapse: Identifies a significant increase in BCR-ABL1 transcript levels in a patient who previously had stable low or undetectable levels.
• Therapeutic Non-Adherence: Detects fluctuations or unexpected rises in transcript levels that may suggest a patient is not taking their TKI medication as prescribed.
• TKI Treatment Resistance: Signals potential kinase domain mutations when transcript levels fail to decline or begin to rise despite therapy.
• Sample Degradation: Detects poor RNA quality or insufficient control gene copies, indicating that the sample was compromised during transport or processing.
• Post-Transplant Engraftment Status: Monitors the disappearance of recipient leukemic clones following allogeneic stem cell transplantation.
• Clonal Evolution Risk: Identifies rapid molecular doubling times that may precede acceleration or blast crisis phases of CML.
• Eligibility for Treatment Discontinuation: Confirms sustained deep molecular response (typically MR4.0 or deeper for 2 or more years) required for safe trial of treatment-free remission.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that waiting for molecular diagnostic results can be a source of anxiety for patients and their families. Because quantitative PCR for BCR-ABL1 involves complex molecular biology techniques—including RNA extraction, complementary DNA (cDNA) synthesis, real-time polymerase chain reaction amplification, and precise mathematical calibration—the processing time is longer than standard hematology tests. Typically, the turnaround time for the BCR-ABL by PCR (Quantitative) report is within 5 to 7 working days from the time of sample collection.

Test Zone Diagnostic Center utilizes a state-of-the-art laboratory information management system (LIMS) to ensure rapid, secure, and convenient access to diagnostic reports. Once the molecular pathology team verifies and signs off on the results, patients receive an automated SMS notification. Reports can be accessed and downloaded directly from the official Test Zone Diagnostic Center online portal using the unique patient ID and password provided on the receipt. Physical copies of the report can also be collected from our main center or designated collection points in Lahore. We ensure that all molecular data is handled with the highest level of clinical confidentiality and security.

BCR-ABL Findings Overview

The following table provides an overview of the parameters evaluated during the BCR-ABL by PCR (Quantitative) assay, along with their corresponding normal and clinical findings:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
BCR-ABL1 Fusion Gene Detection	Not Detected (Negative)	Detected (Positive); confirms presence of Philadelphia chromosome translocation.
BCR-ABL1/ABL1 Ratio (% IS)	0.0000% IS (Undetectable)	>0.0000% IS; indicates active disease, residual disease, or molecular relapse.
ABL1 Control Gene Copy Number	≥10,000 copies (indicates adequate RNA quality)	<10,000 copies; indicates insufficient or degraded RNA, requiring sample recollection.
Major Molecular Response (MMR)	Achieved (BCR-ABL1 ≤ 0.1% IS)	Not Achieved (BCR-ABL1 > 0.1% IS after 12 months of therapy); indicates suboptimal response.
Deep Molecular Response (MR4.5)	Achieved (BCR-ABL1 ≤ 0.0032% IS with adequate control copies)	Not Achieved; indicates persistence of low-level leukemic clones.
Fusion Transcript Isoform Type	None Detected	p210 (b2a2/b3a2) typical of CML; p190 (e1a2) typical of Ph+ ALL; rare p230 (e19a2).
Log Reduction from Baseline	≥3-log reduction (equivalent to MMR or deeper)	<3-log reduction; indicates slow clearance of leukemic cells or therapeutic resistance.
Molecular Response Status	Stable or Undetectable transcript levels	Significant rise (e.g., 1-log increase); suggests loss of response, resistance, or non-adherence.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for BCR-ABL by PCR (Quantitative)?

• Experienced Healthcare Professionals: Our molecular pathology department is led by highly qualified, board-certified molecular pathologists and clinical scientists with extensive experience in hematological oncology diagnostics.
• Patient-Focused Care: We prioritize patient comfort, dignity, and clear communication throughout the diagnostic journey, ensuring a supportive environment during sample collection.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to international laboratory standards, utilizing rigorous internal quality control and external quality assurance programs.
• Professional Reporting: Our reports are structured in strict accordance with international guidelines, presenting BCR-ABL1 transcript percentages on the International Scale (IS) for easy clinical interpretation.
• Modern Diagnostic Approach: We utilize advanced real-time PCR platforms and high-sensitivity assay kits capable of detecting deep molecular responses down to MR4.5 or MR5.0.
• Comfortable Environment: Our modern collection centers in Lahore are designed to provide a clean, hygienic, and stress-free environment for all patients.
• Convenient Location: With easily accessible locations across Lahore, patients can conveniently undergo testing and collect reports without unnecessary travel.
• Commitment to Accurate Diagnosis: We are dedicated to providing timely, precise, and highly reliable molecular results that clinicians can trust to make life-saving treatment decisions.